

2016

# The epidemiology and outcomes of invasive *Candida* infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)

David R. Andes

*University of Wisconsin-Madison*

Nasia Safdar

*University of Wisconsin-Madison*

John W. Baddley

*University of Alabama, Birmingham*

Barbara Alexander

*Duke University*

Lisa Brumble

*Mayo Clinic*

---

Andes, David R.; Safdar, Nasia; Baddley, John W.; Alexander, Barbara; Brumble, Lisa; Freifeld, Allison; Hadley, Susan; Herwaldt, Loreen; Kauffman, Carol; Marshall Lyon, G.; Morrison, Vicki; Patterson, Thomas; Perl, Trish; Walker, Randall; Hess, Tim; Chiller, Tom; Pappas, Peter G.; and The TRANSNET Investigators, "The epidemiology and outcomes of invasive *Candida* infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)" (2016). *Public Health Resources*. 509.

<http://digitalcommons.unl.edu/publichealthresources/509>

This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

*See next page for additional authors*

Follow this and additional works at: <http://digitalcommons.unl.edu/publichealthresources>

---

---

**Authors**

David R. Andes, Nasia Safdar, John W. Baddley, Barbara Alexander, Lisa Brumble, Allison Freifeld, Susan Hadley, Loreen Herwaldt, Carol Kauffman, G. Marshall Lyon, Vicki Morrison, Thomas Patterson, Trish Perl, Randall Walker, Tim Hess, Tom Chiller, Peter G. Pappas, and The TRANSNET Investigators

**ORIGINAL ARTICLE**

# The epidemiology and outcomes of invasive *Candida* infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)

David R. Andes<sup>1</sup> | Nasia Safdar<sup>1</sup> | John W. Baddley<sup>2</sup> | Barbara Alexander<sup>3</sup> |  
 Lisa Brumble<sup>4</sup> | Allison Freifeld<sup>5</sup> | Susan Hadley<sup>6</sup> | Loreen Herwaldt<sup>7</sup> |  
 Carol Kauffman<sup>8</sup> | G. Marshall Lyon<sup>9</sup> | Vicki Morrison<sup>10</sup> | Thomas Patterson<sup>11</sup> |  
 Trish Perl<sup>12</sup> | Randall Walker<sup>4</sup> | Tim Hess<sup>1</sup> | Tom Chiller<sup>13</sup> | Peter G. Pappas<sup>2</sup> |  
 The TRANSNET Investigators

<sup>1</sup>Department of Medicine and Microbiology, University of Wisconsin, Madison, WI, USA

<sup>2</sup>Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

<sup>3</sup>Department of Medicine, Duke University School of Medicine, Durham, NC, USA

<sup>4</sup>Department of Medicine, Mayo Clinic, Rochester, MN, USA

<sup>5</sup>Department of Medicine, University of Nebraska, Lincoln, NE, USA

<sup>6</sup>Department of Medicine, Tufts University, Boston, MA, USA

<sup>7</sup>Department of Medicine, University of Iowa School of Medicine, Iowa City, IA, USA

<sup>8</sup>Department of Medicine, Michigan University School of Medicine, Ann Arbor, MI, USA

<sup>9</sup>Emory University, Atlanta, GA, USA

<sup>10</sup>Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN, USA

<sup>11</sup>Department of Medicine, University of Texas at San Antonio, San Antonio, TX, USA

<sup>12</sup>Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

<sup>13</sup>Centers for Disease Control and Prevention, Atlanta, GA, USA

**Correspondence**

David R. Andes, Department of Medicine and Microbiology, University of Wisconsin Madison, Madison, WI, USA.  
 Email: dra@medicine.wisc.edu

**Abstract**

**Background:** Invasive candidiasis (IC) is a common cause of mortality in solid organ transplant recipients (OTRs), but knowledge of epidemiology in this population is limited.

**Method:** The present analysis describes data from 15 US centers that prospectively identified IC from nearly 17 000 OTRs. Analyses were undertaken to determine predictors of infection and mortality.

**Results:** A total of 639 cases of IC were identified. The most common species was *Candida albicans* (46.3%), followed by *Candida glabrata* (24.4%) and *Candida parapsilosis* (8.1%). In 68 cases >1 species was identified. The most common infection site was bloodstream (44%), followed by intra-abdominal (14%). The most frequently affected allograft groups were liver (41.1%) and kidney (35.3%). All-cause mortality at 90 days was 26.5% for all species and was highest for *Candida tropicalis* (44%) and *C. parapsilosis* (35.2%). Non-white race and female gender were more commonly associated with non-*albicans* species. A high rate of breakthrough IC was seen in patients receiving antifungal prophylaxis (39%). Factors associated with mortality include organ dysfunction, lung transplant, and treatment with a polyene antifungal. The only modifiable factor identified was choice of antifungal drug class based upon infecting *Candida* species.

**Conclusion:** These data highlight the common and distinct features of IC in OTRs.

**KEYWORDS**

*Candida*, solid organ transplant

## 1 | INTRODUCTION

Advances in transplantation biology, organ procurement, surgical techniques, and immunosuppressive therapy have made organ transplantation an effective option for the management of organ failure, with a 1-year survival >60%-80%. However, infection remains one of the most challenging complications of solid organ transplantation.<sup>1-5</sup> The most prevalent mycosis is invasive candidiasis (IC) and is associated with considerable mortality.<sup>6-13</sup> An understanding of the epidemiology and organ transplant type-specific risk factors and outcomes may identify effective prevention and treatment strategies.

The Transplant-Associated Infection Surveillance Network (TRANSNET) was established in 2001 as a prospective surveillance group for the purpose of understanding the burden of invasive fungal infections, and to better define patients at risk and outcome of these infections.<sup>14,15</sup> The group included 15 geographically diverse transplant centers in the United States that provided infection surveillance data for invasive fungal infections in solid organ transplant recipients (OTRs). The emphasis of this report is to examine the epidemiology and outcomes of IC.

## 2 | METHODS

### 2.1 | Study population

Fifteen TRANSNET sites performed transplantation and provided prospective surveillance on these patients. The period of IC infection surveillance was 2001 through 2006, and included all OTRs who developed an IC infection during this period. Information collected on patients included demographics (age, gender, race/ethnicity) and type of transplant. Follow-up information for the cohort was gathered to obtain date of last follow-up and patient status (alive or dead).

### 2.2 | Definitions and case identification

Only proven and probable IC infections as defined by the EORTC/MSG criteria<sup>16,17</sup> were included (see definitions in supplemental Data S1). Lower urinary tract infection and mucosal infections were excluded. Cases were reviewed to determine individual case validity by a Data Review Committee. IC was identified prospectively among this population by establishing monthly patient logs of transplant recipients, reviewing pertinent culture data and histopathology, as well as through the routine contact with transplant physicians and coordinators. Case information included infection site, culture data, method of diagnosis, date and type of transplant, history of rejection, comorbid conditions, cytomegalovirus infection (based on tissue histopathology or viremia), recent immunosuppressive and antifungal treatment data, and patient status at least 3 months after initial diagnosis of IC infection.

### 2.3 | Microbiologic methods

Available cultures and histopathological specimens were processed at the participating hospitals. Species identification was performed using

routine methods at the participants' affiliated laboratories. Available fungal isolates were forwarded to the Centers for Disease Control Mycotic Diseases Branch for confirmation of identification.

### 2.4 | Data analysis

Univariate analyses to assess the relationship between variables and survival were performed by tabulating these measures in the survivor and non-survivor cohorts. The  $\chi^2$  test or the Fisher exact test was used to assess statistical significance for categorical variables and the Wilcoxon rank-sum test was used for continuous variables. Multivariable analyses of factors associated with mortality were performed using stepwise multiple logistic regression via generalized estimating equations. We chose to model the correlation of the repeated measures on some of the individuals with a compound symmetry covariance structure. The criterion for entry into the model was significant at  $\alpha=.20$ , whereas the criterion for remaining in the model was significant at  $\alpha=.05$ . Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. A multiple logistic regression model containing the best predictor variables obtained from the stepwise analysis was then run using all available data in order to obtain more robust estimates of the ORs, 95% CIs, and *P*-values. Once final models were achieved through the stepwise process, a potential interaction between prednisone use and rejection was evaluated by incorporating an interaction term into the final model.

A time-to-death analysis was also performed. First, a univariate analysis comparing transplant type, and another comparing *Candida* species were conducted via Kaplan-Meier estimation and the log-rank test. To validate the above logistic regression results, multivariate analyses were run using Cox regression incorporating the final model terms found in logistic models. All statistical tests were 2-tailed and were performed using a 5% significance level ( $\alpha=.05$ ). Statistical analyses were performed using the R statistical computing environment, version 2.11.

## 3 | RESULTS

### 3.1 | Epidemiology of IC among OTRs

A total of 639 cases of IC (533 proven and 106 probable) occurred in 594 OTRs from among nearly 17 000 patients under surveillance in the study period. The demographic characteristics, transplantation type, and survival in OTRs with IC overall, by transplant type, and *Candida* species, are presented in Table 1. The rank order of most frequently encountered species was *Candida albicans* (46.3%), followed by *Candida glabrata* (24.4%), and *Candida parapsilosis* (8.1%). In 68 cases >1 *Candida* species was involved in IC. The most common site of IC was bloodstream in 44% of cases, followed by intra-abdominal infection (14%). Among the 635 OTRs with IC, infection was observed most commonly in liver (261, 41.1%), followed by kidney (224, 35.3%), kidney-pancreas (58, 9.1%), and lung (55, 8.7%) (4 cases were missing organ type classification). The median time to onset for IC was 80 days post transplantation (interquartile range [IQR] 14-545 days). In total, 205 infections were diagnosed early post transplant (within

**TABLE 1** Characteristics of OTRs with invasive candidiasis infections: univariate analysis based upon *Candida* species

Variable	All species N (%)	<i>C. albicans</i> 296 (46.3)	<i>C. glabrata</i> 156 (24.4)	<i>C. krusei</i> 20 (3.1)	<i>C. parapsilosis</i> 52 (8.1)	<i>C. tropicalis</i> 25 (3.9)	Other	Multiple 68 (10.6)	Non-albicans	P-value <sup>1</sup>
Demographics										
Age, mean±SD	47.4±15.7	47.3±15	49.6±13.1	41.5±20.9	40.3±22	50.6±16.7	44.4±18.6	49.9±14.1	46.8±16.9	.17
Male	361 (57.0)	185 (62.7)	72 (46.5)	1019 (52.6)	33/50 (66.0)	12/24 (50.0)	13/22 (59.1)	36/68 (52.9)	134/261 (51.3)	.03
Female	272 (43.0)	110 (37.3)	83 (53.5)	9/19 (47.4)	17/50 (34.0)	12/24 (50.0)	9/22 (40.9)	32/68 (47.1)	110/295 (37.3)	
Race										
Caucasian	502/611 (82.2)	242/282 (85.8)	121/150 (80.7)	15/20 (75.0)	34/47 (72.3)	15/24 (62.5)	15/21 (71.4)	60/67 (89.6)	194/254 (76.4)	.01
Black	79 (12.4)	26 (8.8)	24 (15.4)	3 (15.0)	9 (17.3)	8 (32.0)	4 (18.2)	5 (7.4)	26 (8.8)	
Other	58 (9.1)	28 (9.5)	11 (7.1)	2 (10.0)	9 (17.3)	2 (8.0)	3 (13.6)	3 (4.4)	28 (9.5)	
Organ										
Heart	48/635 (7.6)	25/294 (8.5)	9/155 (5.8)	2/20 (10.0)	5/52 (9.6)	1/25 (4.0)	3/21 (14.3)	3/68 (4.4)	19/265 (7.2)	.63
Lung	55/635 (8.7)	30/294 (10.2)	9/155 (5.8)	0/20 (0.0)	6/52 (11.5)	6/25 (24.0)	1/21 (4.8)	3/68 (4.4)	21/265 (7.9)	.03
Pancreas	38/635 (6.0)	18/294 (6.1)	13/155 (8.4)	1/20 (5.0)	3/52 (5.8)	0/25 (0.0)	0/21 (0.0)	3/68 (4.4)	17/265 (6.4)	.56
Small bowel	9/635 (1.4)	2/294 (0.7)	4/155 (2.6)	1/20 (5.0)	1/52 (1.9)	1/25 (4.0)	0/21 (0.0)	0/68 (0.0)	7/265 (2.6)	.32
Kidney	224/635 (35.3)	95/294 (32.3)	62/155 (40.0)	6/20 (30.0)	22/52 (42.3)	7/25 (28.0)	11/21 (52.4)	21/68 (30.9)	103/265 (38.9)	.25
Liver	261/635 (41.1)	124/294 (42.2)	58/155 (37.4)	10/20 (50.0)	15/52 (28.8)	10/25 (40.0)	6/21 (28.6)	38/68 (55.9)	98/265 (37.0)	.05
Kidney-pancreas	58/635 (9.1)	27/294 (9.2)	18/155 (11.6)	1/20 (5.0)	3/52 (5.8)	1/25 (4.0)	2/21 (9.5)	6/68 (8.8)	24/265 (9.1)	.8
Comorbidities										
Neutropenia	23/639 (3.6)	12/296 (4.1)	5/156 (3.2)	1/20 (5.0)	4/52 (7.7)	0/25 (0.0)	0/22 (0.0)	1/68 (1.5)	10/266 (3.8)	.48
Fever	338/639 (52.9)	146/296 (49.3)	82/156 (52.6)	10/20 (50.0)	31/52 (59.6)	14/25 (56.0)	14/22 (63.6)	41/68 (60.3)	145/266 (54.5)	.53
Organ rejection	242/635 (38.1)	114/293 (38.9)	55/156 (35.3)	7/20 (35.0)	20/52 (38.5)	10/25 (40.0)	5/21 (23.8)	31/68 (45.6)	96/266 (36.1)	.65
CMV <sup>2</sup>	43/639 (6.7)	14/296 (4.7)	9/156 (5.8)	3/20 (15.0)	3/52 (5.8)	3/25 (12.0)	4/22 (18.2)	7/68 (10.3)	21/266 (7.9)	.08
Renal insufficiency <sup>3</sup>	287/639 (44.9)	133/296 (44.9)	73/156 (46.8)	6/20 (30.0)	22/52 (42.3)	12/25 (48.0)	11/22 (50.0)	30/68 (44.1)	121/266 (45.5)	.87
Hepatic insufficiency <sup>3</sup>	150/639 (23.5)	72/296 (24.3)	38/156 (24.4)	7/20 (35.0)	7/52 (13.5)	3/25 (12.0)	1/22 (4.5)	22/68 (32.4)	55/266 (20.7)	.03
Malnutrition <sup>3</sup>	187/639 (29.3)	92/296 (31.1)	45/156 (28.8)	3/20 (15.0)	13/52 (25.0)	3/25 (12.0)	4/22 (18.2)	27/68 (39.7)	66/266 (24.8)	.08
Diabetes <sup>3</sup>	299/639 (46.8)	143/296 (48.3)	71/156 (45.5)	6/20 (30.0)	21/52 (40.4)	7/25 (28.0)	9/22 (40.9)	42/68 (61.8)	111/266 (41.7)	.04
CHF	51/639 (8.0)	26/296 (8.8)	8/156 (5.1)	0/20 (0.0)	3/52 (5.8)	1/25 (4.0)	1/22 (4.5)	12/68 (17.6)	13/266 (4.9)	.03
Prednisone <sup>1</sup>	469/639 (73.4)	228/296 (77.0)	113/156 (72.4)	12/20 (60.0)	36/52 (69.2)	17/25 (68.0)	15/22 (68.2)	48/68 (70.6)	187/266 (70.3)	.5
MPS <sup>1</sup>	108/639 (16.9)	41/296 (13.9)	35/156 (22.4)	5/20 (25.0)	8/52 (15.4)	2/25 (8.0)	6/22 (27.3)	11/68 (16.2)	55/266 (20.7)	.15
Infection site										
Bloodstream	286/639 (44.8)	95/296 (32.1)	91/156 (58.3)	9/20 (45.0)	40/52 (76.9)	19/25 (76.0)	12/22 (54.5)	20/68 (29.4)	167/266 (62.8)	<.001
Abdominal	90/639 (14.1)	46/296 (15.5)	19/156 (12.2)	2/20 (10.0)	2/52 (3.8)	0/25 (0.0)	2/22 (9.1)	19/68 (27.9)	24/266 (9.0)	<.001
Pulmonary	36/639 (5.6)	26/296 (8.8)	6/156 (3.8)	0/20 (0.0)	1/52 (1.9)	3/25 (12.0)	0/22 (0.0)	0/68 (0.0)	10/266 (3.8)	.01

(Continues)

TABLE 1 (Continued)

Variable	All species N (%)	<i>C. albicans</i> 296 (46.3)	<i>C. glabrata</i> 156 (24.4)	<i>C. krusei</i> 20 (3.1)	<i>C. parapsilosis</i> 52 (8.1)	<i>C. tropicalis</i> 25 (3.9)	Other	Multiple 68 (10.6)	Non- <i>albicans</i> 10/266 (3.8)	P-value <sup>1</sup>
Disseminated	23/639 (3.6)	11/296 (3.7)	8/156 (5.1)	1/20 (5.0)	0/52 (0.0)	1/25 (4.0)	0/22 (0.0)	2/68 (2.9)	10/266 (3.8)	.67
CNS	4/639 (0.6)	3/296 (1.0)	0/156 (0.0)	1/20 (5.0)	0/52 (0.0)	0/25 (0.0)	0/22 (0.0)	0/68 (0.0)	1/266 (0.4)	.18
Antifungal therapy										
Triazole	421/639 (65.9)	226/296 (76.4)	83/156 (53.2)	7/20 (35.0)	34/52 (65.4)	17/25 (68.0)	12/22 (54.5)	42/68 (61.8)	148/266 (55.6)	<.001
Amphotericin B	182/639 (28.5)	73/296 (24.7)	52/156 (33.3)	7/20 (35.0)	16/52 (30.8)	8/25 (32.0)	6/22 (27.3)	20/68 (29.4)	87/266 (32.7)	.59
Echinocandin	229/639 (35.8)	59/296 (19.9)	85/156 (54.5)	10/20 (50.0)	22/52 (42.3)	12/25 (48.0)	6/22 (27.3)	35/68 (51.5)	131/266 (49.2)	<.001
Antifungal prophylaxis <sup>1</sup>										
Triazole	191/639 (29.9)	62/296 (20.9)	66/156 (42.3)	15/20 (75.0)	18/52 (34.6)	7/25 (28.0)	5/22 (22.7)	18/68 (26.5)	110/266 (41.4)	<.001
Amphotericin B	39/639 (6.1)	15/296 (5.1)	9/156 (5.8)	3/20 (15.0)	2/52 (3.8)	4/25 (16.0)	1/22 (4.5)	5/68 (7.4)	18/266 (6.8)	.21
Echinocandin	25/639 (3.9)	9/296 (3.0)	5/156 (3.2)	2/20 (10.0)	6/52 (11.5)	1/25 (4.0)	1/22 (4.5)	1/68 (1.5)	15/266 (5.6)	.06

P-value applies to comparison of variables across species. Non-*albicans* species is excluded from this comparison as it represents a sum of all the non-*albicans* species listed in the table.

<sup>1</sup>Preceding and at the time of invasive candidiasis diagnosis.

<sup>2</sup>CMV in tissue or viremia.

<sup>3</sup>Definitions in supplemental Data S1.

OTR, organ transplant recipient; SD, standard deviation; CMV, cytomegalovirus disease; CHF, congestive heart failure; MPS, methylprednisolone; COPD, chronic obstructive pulmonary disease; CNS, central nervous system.

30 days) and 411 were diagnosed late. The mean patient age was 47.4 years and the majority of patients were Caucasian (82.2%). Several comorbidities were common in cases, including renal (287, 44.9%) and hepatic (150, 23.5%) insufficiency, malnutrition (29.3%), and diabetes (299, 46.8%). In addition, allograft rejection was present in 38% (242) of cases. Patients often received antifungal prophylaxis (nearly 40%) at the time of the diagnosis of IC, most with a triazole (fluconazole most frequent; triazole 29.9%, amphotericin B [AmB] formulation 6.1%, echinocandin 3.9%). For treatment of IC, almost 66% of patients received a triazole, compared with an AmB formulation (28%) or an echinocandin (36%).

### 3.2 | Characteristics of IC among *Candida* species


Survival by *Candida* species varied as shown in Figure 1. The 90-day mortality by species was 22.6% for *C. albicans*, 27.7% for *C. glabrata*, 31.5% for *Candida krusei*, 35.2% for *C. parapsilosis*, and highest for *Candida tropicalis* (44%). Epidemiological features in patients with *C. albicans* (n=296) were contrasted with those who had infection with the second most common species, *C. glabrata* (n=156). Logistic regression identified both female gender and black race as independent demographic predictors of invasive *C. glabrata* infection (Table 2). Triazole antifungal use prior to infection was linked to *C. glabrata* infection.<sup>18-20</sup> The patient age associated with *C. glabrata* in this cohort was 49 years.<sup>21-24</sup> An additional treatment variable associated with *C. glabrata* infection was use of methylprednisolone (MPS).

We also compared patients with *C. albicans* (n=296) to those with the aggregate non-*albicans* species population (n=258). Independent risk factors for IC caused by non-*albicans* species were similar to those for *C. glabrata* alone and included black race, female gender, triazole antifungal prophylaxis, kidney transplant over other types of organ transplant, and MPS use. Distinct risk factors associated with *C. parapsilosis* included younger age (40.3 years, IQR 28.0-58.7). In addition, antifungal prophylaxis with an echinocandin drug was more common in the patients with *C. parapsilosis* breakthrough infections. Among the non-*albicans* species, late disease onset (>90 days) was also most common for *C. parapsilosis* infection.

### 3.3 | Characteristics of IC among transplant organ types

In total, 48 heart, 55 lung, 38 pancreas, 224 kidney, 261 liver, and 58 kidney-pancreas OTRs were diagnosed with IC. The aggregate mortality associated with IC was 26.5%, but was greatest in the heart, lung, and liver transplant cohorts (heart 25.5%, lung 36.4%, liver 30.9%, pancreas 13.2%, kidney 22.3%, kidney-pancreas 15.5%). Allograft rejection was common in the aggregate IC population, but was most common in heart transplant recipients (52.1% vs [32.4%-41.4%]). Use of MPS was also more common in the heart transplant group (33.3% vs [13.8%-18.2%]).

Bloodstream infection was the most common manifestation across the transplant organ types. Intra-abdominal infection was the next most frequent infection site and was associated with allografts below



**FIGURE 1** Kaplan–Meier probability of survival in solid organ transplant (SOT) recipients according to *Candida* species

**TABLE 2** Multivariate analysis of risk factors for infection with select *Candida* species

Variable	Odds ratio	Lower	Upper	P-value
<i>C. albicans</i> vs non- <i>albicans</i> <i>Candida</i>				
Black	0.59	0.35	0.98	.040
Female	0.65	0.44	0.96	.032
Methylprednisolone	0.57	0.33	0.97	.039
Pulmonary site	3.22	1.26	8.24	.015
CHF	2.14	0.92	5.00	.078
Kidney	0.59	0.39	0.90	.015
Pancreatitis disease	2.44	1.02	5.81	.045
Triazole therapy	0.37	0.24	0.57	<.001
<i>C. albicans</i> vs <i>C. glabrata</i>				
Black	0.57	0.31	1.03	.063
Female	0.46	0.29	0.72	.001
Age	0.98	0.97	1.00	.028
Methylprednisolone	0.42	0.24	0.74	.003
Triazole prophylaxis	0.39	0.24	0.62	<.001
<i>Candida parapsilosis</i> vs non- <i>parapsilosis</i> <i>Candida</i>				
Age	0.98	0.96	0.99	.011
Early disease	0.43	0.19	0.95	.037
Echinocandin therapy	4.06	1.47	11.18	.007

CHF, congestive heart failure.



the diaphragm (pancreas 26.3%, liver 20.7%, kidney-pancreas 19%). Antifungal prophylaxis was common among all OTRs with IC (39%); however, this practice was most common for the heart and lung allograft recipients (heart 64.8%, lung 70.9% vs pancreas 28.9%, kidney 29.9%, liver 44.8%, and kidney-pancreas 51.7%). Among patients who developed IC, antifungal prophylaxis with a triazole was most commonly administered to kidney-pancreas transplant (26/58 44.8%) and lung transplant recipients (24/55 43.6%). AmB and echinocandin prophylaxis were much less common in all OTRs. Use of these agents was observed predominantly in the liver transplant cohort (amphotericin 33/261 12.6% and echinocandin 14/261 5.4%).

Triazoles were the most common antifungal drugs used for treatment of IC. This treatment was particularly frequent in pancreas (28/38; 73.7%) and kidney transplant recipients (158/224; 70.5%). Additional characteristics in the different transplant types are shown in Table S1.

### 3.4 | Predictors of mortality in patients with IC

Ninety-day mortality for all patients was 168/635 (26.5%). Kaplan-Meier estimate of 30-day survival was 85.5%. Survival was statistically different among *Candida* species (Figure 1). The mortality for non-*albicans* group was higher than for *C. albicans* (non-*albicans* [80/255] 31.4% vs *C. albicans* [67/296] 22.6%,  $P=.02$ ). Much of this difference was driven by *C. glabrata*. However, mortality associated with *C. parapsilosis* and *C. tropicalis* infection was also high (35.2% and 44% respectively). Independent predictors of mortality in OTRs with IC across all *Candida* species included renal impairment, congestive heart failure, lung transplant, and treatment with an AmB formulation (Table 3). Prednisone use and IC in the early transplant period (30 days) were associated with reduced risk of mortality.

We performed several subgroup analyses to explore unique outcome factors based on *Candida* species, organ transplant type, and infection site (Table 4). The majority of elements correlating with outcome were similar among the organism, host, and disease state groups. Organ dysfunction, infection dissemination, and allograft rejection were shared features among those patients who died. A unique association among the subgroups included the relative protection for patients receiving echinocandins in the setting of *C. glabrata* infection (OR 0.45, 95% CI 0.17-0.97). Conversely, a trend was seen toward reduced efficacy with this antifungal drug class for *C. parapsilosis* infection (61.1% in those that died vs 30.3% in survivors,  $P=.03$ ). Among the renal transplant cohort, the use of AmB was linked to poor outcome (42% in those who died vs other 21.8% in survivors,  $P<.001$ ).

## 4 | DISCUSSION

Infection with *Candida* species was the most common invasive fungal infection among the TRANSNET solid organ transplant population.<sup>14</sup> The present report included surveillance of >15% of organ transplants occurring in the US during the study period, and is among the largest prospective investigations reporting the epidemiology and outcomes

of IC in solid OTRs. The results document the importance of IC for this growing patient population. A common theme includes identification of a high prevalence of comorbidities in this IC population, underscoring the complexity of the patients with IC. Almost 50% of OTRs had renal insufficiency, one-fourth had hepatic dysfunction, nearly 50% had diabetes, and 30% had malnutrition. Nearly 40% experienced episodes of rejection, which may have contributed to the prevalence of organ dysfunction either caused by rejection or anti-rejection therapy. Furthermore, a large percentage of patients had received antifungal prophylaxis prior to development of IC.

Against this backdrop, we found that, similar to other epidemiologic studies of IC, *C. albicans* remained the most frequent pathogen. However, >10% of cases included infection with 2 or more *Candida* species. The frequency in the present study is more than twice that previously reported.<sup>21,25-28</sup> Similar to prior reports, this epidemiologic feature did not impact outcome in this cohort. Over the last 2 decades, the proportion of non-*albicans Candida* species causing IC has steadily increased.<sup>9,26,29-33</sup> The second most common pathogen in the present study was *C. glabrata*.<sup>34-36</sup> The relevance of this increase in non-*albicans* infections relates to potential for reduced treatment efficacy with certain antifungals owing to differences in susceptibility, in particular, the reduced susceptibility of *C. glabrata* and *C. parapsilosis* to triazole and echinocandin antifungal drugs respectively.<sup>37-40</sup> Antifungal susceptibility testing of available isolates demonstrated elevated minimum inhibitory concentrations for these species and drug combinations.<sup>40</sup> Interestingly, outcome for patients infected with non-*albicans* species in this transplant cohort was worse than for those with disease caused by *C. albicans*.

It is notable that we found prophylactic use of drugs from the triazole and echinocandin classes was common for *C. glabrata* and *C. parapsilosis* infections and was statistically associated with poorer outcome for these 2 species. The apparent superiority of the echinocandin class for treatment of IC, including infection caused by *C. glabrata*, has been observed in recent analysis.<sup>41</sup> Reduced efficacy for this class against less susceptible species, such as *C. parapsilosis*, has not been evident in clinical trials.<sup>38,42,43</sup> It is possible that the advanced degree of immunosuppression in this cohort, as suggested by the high rate of both multi-organ failure and allograft rejection, raised the therapeutic hurdle for this pathogen, which is traditionally considered among the least virulent. Indeed, the mortality rate in the transplant population infected with *C. parapsilosis* was unusually high compared to previous reports.<sup>44,45</sup> However, the relatively small number of patients with *C. parapsilosis* in this series precludes drawing firm therapeutic conclusions.

Another unique observation is the relatively young age of patients with *C. glabrata* infections (<50 years). Other large surveillance studies have reported increased *C. glabrata* risk beyond the fifth decade.<sup>20,46,47</sup> This finding may be in part a result of a relatively low percentage of transplant recipients above the fifth decade in this cohort (50.2% age >50 at time of transplant). Two additional unique *C. glabrata* risk factors of note in the current investigation include the relevance of female gender and black race. A similar race observation has been described for cryptococcal infections in the setting of organ transplantation.<sup>48</sup> However, the mechanistic basis for this epidemiologic finding remains unclear. We also observed a correlation between the use of

**TABLE 3** Multivariate analysis of risk factors for mortality in OTRs with invasive candidiasis

Variable	Odds ratio	Lower	Upper	P-value
<i>Candida</i> species subgroup				
All species				
Liver transplant	1.63	0.96	2.76	.071
Renal insufficiency	2.31	1.46	3.66	<.001
Hepatic insufficiency	1.68	0.97	2.91	.066
CHF	3.54	1.61	7.81	.002
Pulmonary site	2.88	1.35	6.16	.006
Prednisone	0.39	0.25	0.63	<.001
Amphotericin B	1.99	1.24	3.2	.004
Early disease	0.51	0.3	0.84	.009
<i>C. albicans</i>				
Heart transplant	0.13	0.03	0.55	.006
Renal insufficiency	3.77	1.82	7.8	<.001
CHF	3.49	1.2	10.11	.022
Pulmonary site	2.88	0.86	9.66	.088
Disseminated site	8.66	1.74	43.01	.008
Prednisone	0.37	0.17	0.8	.012
Methyprednisolone	2.61	0.98	6.93	.054
Amphotericin B	2.85	1.31	6.22	.009
Echinocandin	3.25	1.4	7.58	.006
Early disease	0.36	0.15	0.85	.021
<i>C. glabrata</i>				
Age	1.05	1.02	1.09	.005
Pancreas transplant	9.84	1.46	66.26	.019
CHF	25.06	2.71	232.13	.005
Pulmonary site	5.17	0.68	39.49	.113
Prednisone	0.45	0.18	1.15	.094
Echinocandin	0.4	0.17	0.97	.042
Non- <i>albicans Candida</i>				
Heart	3.86	1.14	13.05	.03
Hepatic insufficiency	3.25	1.6	6.58	.001
CHF	9.02	1.67	48.57	.011
Pulmonary site	5.01	1.76	14.28	.003
Prednisone	0.48	0.25	0.93	.029
Early disease	0.54	0.27	1.09	.084
Transplant organ subgroups				
Kidney				
Hepatic insufficiency	17.28	4.42	67.53	<.001
CHF	6.29	1.89	20.93	.003
Renal insufficiency	3.63	1.39	9.44	.008
Prednisone	0.2	0.07	0.57	.003
Amphotericin	5.47	1.89	15.86	.002
Echinocandin	5.91	0.74	47.14	.093

(Continues)

**TABLE 3** (Continued)

Variable	Odds ratio	Lower	Upper	P-value
Liver				
Renal insufficiency	3.12	1.54	6.32	.002
CMV	13.96	3.2	60.88	<.001
COPD	0.24	0.07	0.84	.026
Disseminated site	4.3	0.92	20.06	.063
Prednisone	0.27	0.13	0.6	.001
Methyprednisolone	0.28	0.09	0.89	.032
Early disease	0.39	0.18	0.86	.02
Candidemia subgroup				
Renal insufficiency	2.24	1.39	3.61	<.001
CHF	3.11	1.38	7.02	.006
Prednisone	0.41	0.25	0.68	<.001
Amphotericin	2.63	1.59	4.37	<.001
Echinocandin	2.01	1.22	3.3	.006
Early disease	0.46	0.27	0.8	.006

OTR, organ transplant recipient; CHF, congestive heart failure; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease.

MPS and non-*albicans Candida* infections, especially those caused by *C. glabrata*. We hypothesize that the use of this higher potency corticosteroid is a marker of organ rejection therapy reflecting enhanced immunosuppression. This observation is congruent with prior studies that link high mortality and *C. tropicalis* infection among patients with hematologic malignancies.<sup>49–51</sup> We did not identify unique transplant variables to explain this observation.

Candidemia was the commonest microbiologic manifestation of IC in this study. The second most common site was intra-abdominal, and not surprisingly, the majority of the cases occurred in abdominal cavity allografts.<sup>52–54</sup> Advanced disease, as marked by categorization as disseminated or organ disease other than abdominal was observed in >10% of patients. This rate of multi-organ involvement is comparable with reports of IC in the non-transplant population.<sup>7,12,52,53</sup> The impact of the pulmonary infection site on outcome is intriguing, but the relevance unclear. We speculate this could be an indication of dissemination or simply a high burden of *Candida*, as suggested in prior colonization studies.

Examination of antifungal choice for prophylaxis and therapy in the current population revealed a use pattern consistent with prior surveys.<sup>12,21,55,56</sup> Prophylaxis was dominated by the triazole class, predominantly fluconazole. Definitive treatment represented a mixed approach, and included a high percentage of echinocandins and comparatively little use of polyenes, probably owing to the differential risk for nephrotoxicity. Triazole prophylaxis in this cohort was successful in the prevention of IC by *C. albicans*, as previously reported.<sup>56–59</sup> However, the rate of breakthrough IC cases in this cohort was striking. Analyses demonstrated that many emergent infections were caused by species with higher minimum inhibitory concentrations to antifungal compounds.<sup>42</sup> In the setting of triazole prophylaxis, infection with

**TABLE 4** Characteristics of OTRs with invasive candidiasis based upon transplant organ

Variable	Heart	Lung	Pancreas	Kidney	Liver	Kidney-pancreas
Demographics						
Age, mean±SD	52.8±19.3	48.2±15.7	44.5±7.5	48.1±12.9	46.9±17.1	42.6±9.1
Male	35/48 (72.9)	22/54 (40.7)	19/37 (51.4)	112/222 (50.5)	164/259 (63.3)	30/58 (51.7)
Female	13/48 (27.1)	32/54 (59.3)	18/37 (48.6)	110/222 (49.5)	95/259 (36.7)	28/58 (48.3)
Race						
Caucasian	39 (83.0)	43 (78.2)	37 (97.4)	167 (74.6)	204 (78.8)	48 (82.8)
Black	3 (6.4)	7 (12.7)	0 (0.0)	43 (19.2)	23 (8.9)	7 (12.1)
Other	5 (10.6)	5 (9.1)	1 (2.6)	14 (6.2)	32 (12.4)	3 (5.2)
Comorbidities						
Neutropenia	1/48 (2.1)	1/55 (1.8)	2/38 (5.3)	7/224 (3.1)	12/261 (4.6)	2/58 (3.4)
Fever	20/48 (41.7)	19/55 (34.5)	26/38 (68.4)	115/224 (51.3)	148/261 (56.7)	34/58 (58.6)
Organ rejection	25/48 (52.1)	22/55 (40.0)	12/37 (32.4)	87/224 (38.8)	88/260 (33.8)	24/58 (41.4)
CMV	4/48 (8.3)	4/55 (7.3)	2/38 (5.3)	12/224 (5.4)	20/261 (7.7)	3/58 (5.2)
Renal insufficiency	33/48 (68.8)	23/55 (41.8)	8/38 (21.1)	106/224 (47.3)	116/261 (44.4)	22/58 (37.9)
Hepatic insufficiency	6/48 (12.5)	2/55 (3.6)	1/38 (2.6)	29/224 (12.9)	111/261 (42.5)	6/58 (10.3)
Malnutrition	4/48 (8.3)	10/55 (18.2)	6/38 (15.8)	67/224 (29.9)	95/261 (36.4)	19/58 (32.8)
Diabetes	28/48 (58.3)	18/55 (32.7)	12/38 (31.6)	108/224 (48.2)	130/261 (49.8)	26/58 (44.8)
COPD	3/48 (6.2)	13/55 (23.6)	0/38 (0.0)	16/224 (7.1)	29/261 (11.1)	3/58 (5.2)
CHF	9/48 (18.8)	3/55 (5.5)	2/38 (5.3)	25/224 (11.2)	12/261 (4.6)	5/58 (8.6)
Autoimmune	3/48 (6.2)	6/55 (10.9)	0/38 (0.0)	19/224 (8.5)	15/261 (5.7)	2/58 (3.4)
Pancreatitis	2/48 (4.2)	0/55 (0.0)	2/38 (5.3)	30/224 (13.4)	11/261 (4.2)	11/58 (19.0)
HIV/AIDS	0/48 (0.0)	0/55 (0.0)	0/38 (0.0)	2/224 (0.9)	0/261 (0.0)	0/58 (0.0)
Prednisone	31/48 (64.6)	45/55 (81.8)	26/38 (68.4)	178/224 (79.5)	180/261 (69.0)	43/58 (74.1)
MPS	16/48 (33.3)	10/55 (18.2)	6/38 (15.8)	33/224 (14.7)	42/261 (16.1)	8/58 (13.8)
<i>Candida</i> species						
<i>C. albicans</i>	25 (53.2)	30 (54.5)	18 (47.4)	95 (42.4)	124 (47.9)	27 (46.6)
<i>C. glabrata</i>	9 (19.1)	9 (16.4)	13 (34.2)	62 (27.7)	57 (22.0)	18 (31.0)
<i>C. krusei</i>	2 (4.3)	0 (0.0)	1 (2.6)	6 (2.7)	9 (3.5)	1 (1.7)
<i>C. parapsilosis</i>	4 (8.5)	6 (10.9)	3 (7.9)	22 (9.8)	15 (5.8)	3 (5.2)
<i>C. tropicalis</i>	1 (2.1)	6 (10.9)	0 (0.0)	7 (3.1)	10 (3.9)	1 (1.7)
<i>C. lusitanae</i>	1 (2.1)	0 (0.0)	0 (0.0)	3 (1.3)	1 (0.4)	0 (0.0)
Multiple	3 (6.4)	3 (5.5)	3 (7.9)	21 (9.4)	38 (14.7)	6 (10.3)
Other	1 (2.1)	0 (0.0)	0 (0.0)	3 (1.3)	4 (1.5)	1 (1.7)
Unspecified	1 (2.1)	1 (1.8)	0 (0.0)	5 (2.2)	1 (0.4)	1 (1.7)
Infection site						
Bloodstream	31/48 (64.6)	29/55 (52.7)	12/38 (31.6)	99/224 (44.2)	107/261 (41.0)	15/58 (25.9)
Abdominal	0/48 (0.0)	0/55 (0.0)	10/38 (26.3)	26/224 (11.6)	54/261 (20.7)	11/58 (19.0)
Pulmonary	4/48 (8.3)	17/55 (30.9)	1/38 (2.6)	3/224 (1.3)	9/261 (3.4)	1/58 (1.7)
Disseminated	3/48 (6.2)	0/55 (0.0)	1/38 (2.6)	9/224 (4.0)	10/261 (3.8)	2/58 (3.4)
CNS	0/48 (0.0)	0/55 (0.0)	0/38 (0.0)	3/224 (1.3)	1/261 (0.4)	0/58 (0.0)
Antifungal therapy <sup>1</sup>						
Triazole	31/48 (64.6)	38/55 (69.1)	28/38 (73.7)	158/224 (70.5)	158/261 (60.5)	39/58 (67.2)
Amphotericin	14/48 (29.2)	15/55 (27.3)	9/38 (23.7)	59/224 (26.3)	82/261 (31.4)	17/58 (29.3)
Echinocandin	13/48 (27.1)	10/55 (18.2)	14/38 (36.8)	85/224 (37.9)	102/261 (39.1)	24/58 (41.4)

(Continues)

**TABLE 4** (Continued)

Variable	Heart	Lung	Pancreas	Kidney	Liver	Kidney-pancreas
Antifungal prophylaxis						
Triazole	19/48 (39.6)	24/55 (43.6)	11/38 (28.9)	58/224 (25.9)	70/261 (26.8)	26/58 (44.8)
Amphotericin	2/48 (4.2)	12/55 (21.8)	0/38 (0.0)	2/224 (0.9)	33/261 (12.6)	1/58 (1.7)
Echinocandin	1/48 (2.1)	3/55 (5.5)	0/38 (0.0)	7/224 (3.1)	14/261 (5.4)	3/58 (5.2)

<sup>1</sup>Includes sequential or combination therapy.

OTR, organ transplant recipient; SD, standard deviation; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; MPS, methylprednisolone; CNS, central nervous system.

*C. glabrata* was common. This observation is congruent with previously reported prophylaxis studies.<sup>18</sup> Interestingly, we also found an association between echinocandin prophylaxis and infection with *C. parapsilosis* (6/52, 11.5%), and this finding is consistent with the reduced efficacy described in the setting of definitive therapy described above.

A number of comorbidities were strongly related to poor outcomes. Neutropenia, heart failure, and renal and hepatic dysfunction each conferred a negative impact on outcome. Interestingly, we found a disparate impact for 2 corticosteroid formulations, prednisone and MPS. As noted above, we theorize that use of MPS is a marker of rejection and this likely translates into a risk for poor outcome. Conversely, use of prednisone may suggest stable allograft function and may explain the observed “protective” nature of this therapy. Early disease was also predictive of a favorable outcome. We theorize that this improvement may be a result of earlier diagnosis linked to enhanced vigilance in the early post-transplant period.

The results of this survey both confirm and extend our understanding of the features of IC in solid OTRs. We identified a hierarchy of risk for disease and outcome based on transplant type, underlying disease, and comorbid conditions. We did not identify directly modifiable factors, other than an emphasis on the importance of drug selection for certain *Candida* species, which is intuitive based upon fairly predictable antifungal drug susceptibility. Current evidence suggests that echinocandins are the optimal empiric antifungal drug choice for IC.<sup>43</sup> In the current study, this benefit is less clear for infection caused by *C. parapsilosis*, but numbers are small. The absence of other readily identifiable factors under the direct control of clinicians underscores the importance of a high index of suspicion in this complex patient population. In particular, the presence of organ dysfunction and rejection should prompt surveillance for this infectious complication. Furthermore, these observations highlight the need for improved fungal diagnostics and more effective antifungal compounds.

The TRANSNET database is comprehensive, but it has several limitations. Baseline and longitudinal laboratory data were minimal and specific information about drug exposure was incomplete. For example, information regarding antifungal, antiviral, and antibacterial prophylaxis was limited, as were data pertaining to vascular catheter management, immunosuppressive regimens, and institution-specific practices and protocols. It is possible that information regarding catheters may have shed light on the relatively high mortality linked to *C. parapsilosis* infection. Moreover, the dataset does not include data on disease severity and transplant incompatibility characteristics.

These important covariates should be explored more fully in future studies. In addition, the period of data collection ended in 2006, thus practice changes may have occurred that limit extrapolation of findings. For example, echinocandins have emerged as the preferred therapy for treatment of IC over AmB and triazoles. Immunosuppressive and antifungal prophylaxis regimens also continue to evolve. Finally, this analysis is based on all-cause mortality, as attribution to IC as a contributing cause to mortality is difficult, and generally reflects investigator opinion. Despite these limitations, this analysis from a large and comprehensive database provides important insights into factors that are associated with mortality among OTRs who develop IC, and these data may be useful in developing strategies for prevention and treatment of this important post-transplantation complication.

## REFERENCES

- Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. *Am J Transplant.* 2008;8:1737–1743.
- Moreno A, Cervera C, Gavalda J, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. *Am J Transplant.* 2007;7:2579–2586.
- Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. *Am J Transplant.* 2009;9:835–843.
- Aberg F, Makisalo H, Hockerstedt K, Isoniemi H. Infectious complications more than 1 year after liver transplantation: a 3-decade nationwide experience. *Am J Transplant.* 2011;11:287–295.
- Lumbreras C, Fernandez I, Velosa J, Munn S, Sterioff S, Paya CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. *Clin Infect Dis.* 1995;20:514–520.
- Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. *Am J Transplant.* 2006;6:386–391.
- Paya CV. Fungal infections in solid-organ transplantation. *Clin Infect Dis.* 1993;16:677–688.
- Fortun J, Lopez-San Roman A, Velasco JJ, et al. Selection of *Candida glabrata* strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. *Eur J Clin Microbiol Infect Dis.* 1997;16:314–318.
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev.* 2007;20:133–163.
- Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. *Infect Control Hosp Epidemiol.* 2005;26:540–547.

11. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. *Clin Infect Dis.* 2005;41:1232–1239.
12. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. *Clin Infect Dis.* 2009;48:1695–1703.
13. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. *Clin Infect Dis.* 1995;20:1531–1534.
14. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Clin Infect Dis.* 2010;50:1101–1111.
15. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. *Clin Infect Dis.* 2010;50:1091–1100.
16. Ascoglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin Infect Dis.* 2002;34:7–14.
17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis.* 2008;46:1813–1821.
18. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of *Torulopsis glabrata* infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. *Antimicrob Agents Chemother.* 1993;37:1847–1849.
19. Uzun O, Ascoglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. *Clin Infect Dis.* 2001;32:1713–1717.
20. Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of *Candida glabrata* to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. *J Clin Microbiol.* 2009;47:3185–3190.
21. Pfaller MA, Andes DR, Diekema DJ, et al. Epidemiology and outcomes of invasive candidiasis due to non-*albicans* species of *Candida* in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004–2008. *PLoS One.* 2014;9:e101510.
22. Klevay MJ, Ernst EJ, Hollanbaugh JL, Miller JG, Pfaller MA, Diekema DJ. Therapy and outcome of *Candida glabrata* versus *Candida albicans* bloodstream infection. *Diagnost Microbiol Infect Dis.* 2008;60:273–277.
23. Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004–2008. *Diagnost Microbiol Infect Dis.* 2012;74:323–331.
24. Fidel PL Jr, Vazquez JA, Sobel JD. *Candida glabrata*: review of epidemiology, pathogenesis, and clinical disease with comparison to *C. albicans*. *Clin Microbiol Rev.* 1999;12:80–96.
25. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis.* 2003;37:634–643.
26. Kim SH, Yoon YK, Kim MJ, Sohn JW. Risk factors for and clinical implications of mixed *Candida*/bacterial bloodstream infections. *Clin Microbiol Infect.* 2013;19:62–68.
27. Pulimood S, Ganesan L, Alangaden G, Chandrasekar P. Polymicrobial candidemia. *Diagn Microbiol Infect Dis.* 2002;44:353–357.
28. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. Polymicrobial bloodstream infections involving *Candida* species: analysis of patients and review of the literature. *Diagn Microbiol Infect Dis.* 2007;59:401–406.
29. Cleveland AA, Farley MM, Harrison LH, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. *Clin Infect Dis.* 2012;55:1352–1361.
30. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of *albicans* and the various non-*albicans Candida spp* among candidemia isolates from inpatients in various parts of the world: a systematic review. *Int J Infect Dis.* 2010;14:e954–e966.
31. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-*Candida albicans* species and antifungal resistance. *Am J Med.* 1996;100:617–623.
32. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer.* 2008;112:2493–2499.
33. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. *Clin Infect Dis.* 2002;35:627–630.
34. Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of *Candida* bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. *J Clin Microbiol.* 2005;43:1829–1835.
35. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to *Candida* species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. *J Clin Microbiol.* 1998;36:1886–1889.
36. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to *Candida* species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997–1998. *Antimicrob Agents Chemother.* 2000;44:747–751.
37. Morrison VA. Echinocandin antifungals: review and update. *Expert Rev Anti Infect Ther.* 2006;4:325–342.
38. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. *Antimicrob Agents Chemother.* 2011;55:532–538.
39. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of *Candida* species to anidulafungin, caspofungin, and micafungin. *J Clin Microbiol.* 2011;49:624–629.
40. Lockhart SR, Wagner D, Iqbal N, et al. Comparison of *in vitro* susceptibility characteristics of *Candida* species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. *J Clin Microbiol.* 2011;49:2404–2410.
41. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis.* 2012;54:1110–1122.
42. Forrest GN, Weekes E, Johnson JK. Increasing incidence of *Candida parapsilosis* candidemia with caspofungin usage. *J Infect.* 2008;56:126–129.
43. Reboli AC. Editorial commentary: Is the debate about treatment of *Candida parapsilosis* complex infections with echinocandins much ado about nothing? *Clin Infect Dis.* 2014;58:1422–1423.
44. Weems JJ Jr. *Candida parapsilosis*: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. *Clin Infect Dis.* 1992;14:756–766.
45. Trofa D, Gacser A, Nosanchuk JD. *Candida parapsilosis*, an emerging fungal pathogen. *Clin Microbiol Rev.* 2008;21:606–625.
46. Pfaller MA, Messer SA, Boyken L, Tendolcar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of *Candida glabrata* to fluconazole according to patient age and geographic location. *J Clin Microbiol.* 2003;41:2176–2179.



47. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of *Candida glabrata*: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. *Diagn Microbiol Infect Dis*. 2010;67:162–171.
48. Boehme AK, McGwin G, Andes DR, et al. Race and invasive fungal infection in solid organ transplant recipients. *Ethn Dis*. 2014;24:382–385.
49. Weinberger M, Leibovici L, Perez S, et al. Characteristics of candidaemia with *Candida-albicans* compared with non-*albicans* *Candida* species and predictors of mortality. *J Hosp Infect*. 2005;61:146–154.
50. Leung AY, Chim CS, Ho PL, et al. *Candida tropicalis* fungaemia in adult patients with haematological malignancies: clinical features and risk factors. *J Hosp Infect*. 2002;50:316–319.
51. Husain S, Tollemar J, Dominguez EA, et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. *Transplantation*. 2003;75:2023–2029.
52. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. *Medicine*. 1988;67:132–143.
53. Patel R, Portela D, Badley AD, et al. Risk factors of invasive *Candida* and non-*Candida* fungal infections after liver transplantation. *Transplantation*. 1996;62:926–934.
54. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. *Transpl Infect Dis*. 2010;12:220–229.
55. Cornely OA, Gachot B, Akan H, et al.; EORTC Infectious Diseases Group. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). *Clin Infect Dis*. 2015;61:324–331.
56. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48:503–535.
57. Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. *Am J Transplant*. 2014;14:2758–2764.
58. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. *Blood*. 2000;96:2055–2061.
59. Winston DJ, Pakrasi A, Busuttill RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1999;131:729–737.

## SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

**How to cite this article:** Andes, D.R., Safdar, N., Baddley, J.W., Alexander, B., Brumble, L., Freifeld, A., Hadley, S., Herwaldt, L., Kauffman, C., Lyon, G.M., Morrison, V., Patterson, T., Perl, T., Walker, R., Hess, T., Chiller, T., Pappas, P.G. and The TRANSNET Investigators (2016), The epidemiology and outcomes of invasive *Candida* infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). *Transplant Infectious Disease*, 18: 921–931. doi: 10.1111/tid.12613

**Supplemental TABLE S1. Characteristics of OTR patients with invasive candidiasis based upon transplant organ**

Variable	Heart	Lung	Pancreas	Kidney	Liver	Kidney-Pancreas
<b>Demographics</b>						
Age mean ± SD	52.8 ± 19.3	48.2 ± 15.7	44.5 ± 7.5	48.1 ± 12.9	46.9 ± 17.1	42.6 ± 9.1
Male	35/48 (72.9)	22/54 (40.7)	19/37 (51.4)	112/222 (50.5)	164/259 (63.3)	30/58 (51.7)
Female	13/48 (27.1)	32/54 (59.3)	18/37 (48.6)	110/222 (49.5)	95/259 (36.7)	28/58 (48.3)
<b>Race</b>						
Caucasian	39 (83.0)	43 (78.2)	37 (97.4)	167 (74.6)	204 (78.8)	48 (82.8)
Black	3 (6.4)	7 (12.7)	0 (0.0)	43 (19.2)	23 (8.9)	7 (12.1)
Other	5 (10.6)	5 (9.1)	1 (2.6)	14 (6.2)	32 (12.4)	3 (5.2)
<b>Comorbidities</b>						
Neutropenia	1/48 (2.1)	1/55 (1.8)	2/38 (5.3)	7/224 (3.1)	12/261 (4.6)	2/58 (3.4)
Fever	20/48 (41.7)	19/55 (34.5)	26/38 (68.4)	115/224 (51.3)	148/261 (56.7)	34/58 (58.6)
Organ Rejection	25/48 (52.1)	22/55 (40.0)	12/37 (32.4)	87/224 (38.8)	88/260 (33.8)	24/58 (41.4)
CMV	4/48 (8.3)	4/55 (7.3)	2/38 (5.3)	12/224 (5.4)	20/261 (7.7)	3/58 (5.2)
Renal insufficiency	33/48 (68.8)	23/55 (41.8)	8/38 (21.1)	106/224 (47.3)	116/261 (44.4)	22/58 (37.9)
Hepatic insufficiency	6/48 (12.5)	2/55 (3.6)	1/38 (2.6)	29/224 (12.9)	111/261 (42.5)	6/58 (10.3)
Malnutrition	4/48 (8.3)	10/55 (18.2)	6/38 (15.8)	67/224 (29.9)	95/261 (36.4)	19/58 (32.8)
Diabetes	28/48 (58.3)	18/55 (32.7)	12/38 (31.6)	108/224 (48.2)	130/261 (49.8)	26/58 (44.8)
COPD	3/48 (6.2)	13/55 (23.6)	0/38 (0.0)	16/224 (7.1)	29/261 (11.1)	3/58 (5.2)
CHF	9/48 (18.8)	3/55 (5.5)	2/38 (5.3)	25/224 (11.2)	12/261 (4.6)	5/58 (8.6)
Autoimmune	3/48 (6.2)	6/55 (10.9)	0/38 (0.0)	19/224 (8.5)	15/261 (5.7)	2/58 (3.4)
Pancreatitis	2/48 (4.2)	0/55 (0.0)	2/38 (5.3)	30/224 (13.4)	11/261 (4.2)	11/58 (19.0)

Variable	Heart	Lung	Pancreas	Kidney	Liver	Kidney-Pancreas
HIV/AIDS	0/48 (0.0)	0/55 (0.0)	0/38 (0.0)	2/224 (0.9)	0/261 (0.0)	0/58 (0.0)
Prednisone	31/48 (64.6)	45/55 (81.8)	26/38 (68.4)	178/224 (79.5)	180/261 (69.0)	43/58 (74.1)
Methylpred	16/48 (33.3)	10/55 (18.2)	6/38 (15.8)	33/224 (14.7)	42/261 (16.1)	8/58 (13.8)
<b>Candida species</b>						
<i>C. albicans</i>	25 (53.2)	30 (54.5)	18 (47.4)	95 (42.4)	124 (47.9)	27 (46.6)
<i>C. glabrata</i>	9 (19.1)	9 (16.4)	13 (34.2)	62 (27.7)	57 (22.0)	18 (31.0)
<i>C. krusei</i>	2 (4.3)	0 (0.0)	1 (2.6)	6 (2.7)	9 (3.5)	1 (1.7)
<i>C. parapsilosis</i>	4 (8.5)	6 (10.9)	3 (7.9)	22 (9.8)	15 (5.8)	3 (5.2)
<i>C. tropicalis</i>	1 (2.1)	6 (10.9)	0 (0.0)	7 (3.1)	10 (3.9)	1 (1.7)
<i>C. lusitaniae</i>	1 (2.1)	0 (0.0)	0 (0.0)	3 (1.3)	1 (0.4)	0 (0.0)
Multiple	3 (6.4)	3 (5.5)	3 (7.9)	21 (9.4)	38 (14.7)	6 (10.3)
Other	1 (2.1)	0 (0.0)	0 (0.0)	3 (1.3)	4 (1.5)	1 (1.7)
unspecified	1 (2.1)	1 (1.8)	0 (0.0)	5 (2.2)	1 (0.4)	1 (1.7)
<b>Infection site</b>						
Bloodstream	31/48 (64.6)	29/55 (52.7)	12/38 (31.6)	99/224 (44.2)	107/261 (41.0)	15/58 (25.9)
Abdominal	0/48 (0.0)	0/55 (00.0)	10/38 (26.3)	26/224 (11.6)	54/261 (20.7)	11/58 (19.0)
Pulmonary	4/48 (8.3)	17/55 (30.9)	1/38 (2.6)	3/224 (1.3)	9/261 (3.4)	1/58 (1.7)
Disseminated	3/48 (6.2)	0/55 (0.0)	1/38 (2.6)	9/224 (4.0)	10/261 (3.8)	2/58 (3.4)
CNS	0/48 (0.0)	0/55 (0.0)	0/38 (0.0)	3/224 (1.3)	1/261 (0.4)	0/58 (0.0)
<b>Antifungal therapy*</b>						
Triazole	31/48 (64.6)	38/55 (69.1)	28/38 (73.7)	158/224 (70.5)	158/261 (60.5)	39/58 (67.2)
Amphotericin	14/48 (29.2)	15/55 (27.3)	9/38 (23.7)	59/224 (26.3)	82/261 (31.4)	17/58 (29.3)
Echinocandin	13/48 (27.1)	10/55 (18.2)	14/38 (36.8)	85/224 (37.9)	102/261 (39.1)	24/58 (41.4)



Variable	Heart	Lung	Pancreas	Kidney	Liver	Kidney-Pancreas
<b>Antifungal prophylaxis</b>						
Triazole	19/48 (39.6)	24/55 (43.6)	11/38 (28.9)	58/224 (25.9)	70/261 (26.8)	26/58 (44.8)
Amphotericin	2/48 (4.2)	12/55 (21.8)	0/38 (0.0)	2/224 (0.9)	33/261 (12.6)	1/58 (1.7)
Echinocandin	1/48 (2.1)	3/55 (5.5)	0/38 (0.0)	7/224 (3.1)	14/261 (5.4)	3/58 (5.2)

\*Includes sequential or combination therapy.

OTR, organ transplant recipients; SD, standard deviation; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; CMV, cytomegalovirus; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; Methylpred, methylprednisolone; CNS, central nervous system.

## **Supplemental Data:**

### **Co-Morbidity Definitions:**

#### **Diabetes**

Any patient requiring oral hypoglycemic agents or insulin to maintain control of blood sugar will be defined as having diabetes mellitus. Among patients receiving total parenteral nutrition (TPN) who develop hyperglycemia only during periods in which they are receiving TPN should **not** be considered in this category. Patients who develop post-transplantation diabetes due to glucocorticosteroids or other factors and who require oral agents or insulin for blood sugar control should be included.

#### **Malnutrition**

A serum albumin of  $\leq 2$  g/dL will be sufficient to make a diagnosis of malnutrition. For patient with serum albumin between 2.1 and 2.5 g/dL, malnutrition will be considered if the patient is  $\leq 5\%$  below ideal body weight.

#### **Chronic Renal Insufficiency**

Renal insufficiency will be defined as patients with either a chronically elevated serum creatinine of  $\geq 3.0$  or a creatinine clearance  $\leq 30$  cc/min.

#### **Hepatic Insufficiency**

Hepatic insufficiency will be defined in clinical terms as the presence of ascites without other cause, typical stigmata of chronic liver disease including jaundice, spider angiomas, peripheral wasting, etc. Laboratory evidence of hepatic insufficiency may include any of the following: elevated serum ammonia, direct hyperbilirubinemia, and evidence of decreased protein synthetic function as evidenced by hypoalbuminemia or prolonged prothrombin time (increased INR).

#### **Pancreatitis**

Acute or chronic pancreatitis will be defined by abnormal lipase or amylase assays, or radiologic evidence revealing pancreatic inflammation or calcification.

#### **Definition of Proven Invasive Candidiasis:**

Histopathologic, cytopathologic, or direct microscopic examination of a specimen obtained by needle aspiration or biopsy from a normally sterile site (other than mucous membranes) showing yeast cells—for example, *Candida* species showing pseudohyphae or true hyphae.

*or*

Recovery of a yeast by culture of a sample obtained by a sterile procedure (including a freshly placed [ $<24$  h ago] drain) from a normally sterile site showing a clinical or radiological abnormality consistent with an infectious disease process.

*or*

Blood culture that yields *Candida* species.

**Definition Probable Invasive Candidiasis:** Requires the presence of a host factor, a clinical criterion, and a mycological criterion. Cases that meet the criteria for a host factor and a clinical criterion but for which mycological criteria are absent are considered possible invasive fungal disease.

### Host factors

- Recent history of neutropenia ( $<0.5 \times 10^9$  neutrophils/L [ $<500$  neutrophils/ $\text{mm}^3$ ] for  $>10$  days) temporally related to the onset of fungal disease
- Receipt of an allogeneic stem cell transplant
- Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for  $>3$  weeks
- Treatment with other recognized T cell immunosuppressants, such as cyclosporine, tumor necrosis factor- $\alpha$  blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days
- Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)

### Clinical criteria

Acute localized pain (including pain radiating to the eye)

Central nervous system infection

1 of the following 2 signs:

Focal lesions on imaging

Meningeal enhancement on magnetic resonance imaging or computed tomography

### Disseminated candidiasis

At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:  
Small, target-like abscesses (bull's-eye lesions) in liver or spleen or progressive retinal exudates on ophthalmologic examination

### Mycological criteria

Direct test (cytology, direct microscopy, or culture)